Mark Roschewski, MD, National Institutes of Health, Bethesda, MD, discusses the benefits of monitoring circulating tumor DNA (ctDNA) in patients with Hodgkin lymphoma (HL), which can be indicative of patient outcomes. Dr Roschewski comments on the potential role of ctDNA detection in modifying treatments for individual patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
